Sep 9, 2026, 06:00 UTC
Evotec SE initiated a Phase 1 clinical trial for JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its subsidiary Just - Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program.
Source:Sep 2, 2026, 06:04 UTC
Evotec SE and Plectonic Biotech announced a research collaboration to explore a novel immunotherapy approach for solid tumors, combining Evotec's BiTco costimulatory CD2 bispecifics platform with Plectonic's LOGIBODY® technology.
Source:Aug 6, 2026, 06:16 UTC
Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases using Evotec's AI-enabled discovery platform.
Source:Jul 13, 2026, 19:43 UTC
Evotec SE announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook.
Source:Jun 30, 2026, 06:16 UTC
Just - Evotec Biologics launched J.TRAIN, a turnkey continuous manufacturing offering for biologics, enabling deployment of its proprietary platform in partner-owned facilities.
Source: